Studies being presented at the American Society of Clinical Oncology’s 2026 annual meeting, being held May 29 to June 2 in Chicago, will highlight how GLP-1s could reshape oncology care, with research linking the drugs to lower cancer incidence and better outcomes across several tumor types.
Once viewed primarily as weight loss and diabetes drugs, GLP-1 medications are drawing increased scrutiny in oncology. Leaders are beginning to examine what the drugs could mean for cancer risk and outcomes, as a growing body of research suggests the effects may be more nuanced — and in some cases more promising — than initially expected.
Here are four studies to note:
- A study out of Philadelphia-based Penn Medicine found GLP-1 use was associated with a significantly lower incidence of breast cancer among 94,827 women between Jan. 1, 2022, and June 30, 2025.
- A study out of Cleveland Clinic found GLP-1 use among 10,225 patients with stage 1 to 3 cancers was associated with reduced disease progression across breast, prostate, colorectal, pancreatic, liver and non-small cell lung cancers.
The most statistically significant reductions were seen in non-small cell lung, breast, colorectal and liver cancers. - A study out of Richmond, Va.-based VCU Massey Comprehensive Cancer Center found that among 20,383 patients with stage 1 to 3 colorectal cancer, GLP-1 use was associated with improved recurrence-free survival and overall survival compared to nonusers.
- A study out of Jacksonville-based Mayo Clinic Florida found that GLP-1 use among patients with endometrial cancer and comorbid obesity was associated with lower rates of overall mortality, sepsis, and peritoneal, lymph node and visceral metastases.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
